Corvus Pharmaceuticals Stock Performance
| CRVS Stock | USD 4.25 0.06 1.39% |
The firm shows a Beta (market volatility) of 0.53, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Corvus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Corvus Pharmaceuticals is expected to be smaller as well. At this point, Corvus Pharmaceuticals has a negative expected return of -0.16%. Please make sure to confirm Corvus Pharmaceuticals' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Corvus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Corvus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (1.39) | Five Day Return (2.07) | Year To Date Return (21.73) | Ten Year Return (70.18) | All Time Return (70.18) |
1 | Were Not Worried About Corvus Pharmaceuticals Cash Burn | 01/07/2025 |
2 | Acquisition by Adams Street Partners Llc of 15000 shares of Corvus Pharmaceuticals at 0.965 subject to Rule 16b-3 | 01/15/2025 |
3 | Analysts Set Corvus Pharmaceuticals, Inc. PT at 12.38 - MarketBeat | 01/27/2025 |
4 | When Moves Investors should Listen - Stock Traders Daily | 02/13/2025 |
5 | Corvus Pharmaceuticals Small Market, Many Competitors, Low Cash Balance - Seeking Alpha | 03/03/2025 |
6 | Acquisition by William Jones of 19357 shares of Corvus Pharmaceuticals at 3.5 subject to Rule 16b-3 | 03/04/2025 |
7 | Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome | 03/12/2025 |
8 | Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 ... | 03/17/2025 |
9 | Corvus Pharmaceuticals to Present at the H.C. ... | 03/19/2025 |
10 | Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 11b Clinical ... | 03/20/2025 |
| Begin Period Cash Flow | 13.2 M |
Corvus |
Corvus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 490.00 in Corvus Pharmaceuticals on December 24, 2024 and sell it today you would lose (65.00) from holding Corvus Pharmaceuticals or give up 13.27% of portfolio value over 90 days. Corvus Pharmaceuticals is currently does not generate positive expected returns and assumes 3.8017% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Corvus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Corvus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Corvus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Corvus Pharmaceuticals, and traders can use it to determine the average amount a Corvus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0427
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CRVS |
Estimated Market Risk
| 3.8 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Corvus Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Corvus Pharmaceuticals by adding Corvus Pharmaceuticals to a well-diversified portfolio.
Corvus Pharmaceuticals Fundamentals Growth
Corvus Stock prices reflect investors' perceptions of the future prospects and financial health of Corvus Pharmaceuticals, and Corvus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Corvus Stock performance.
| Return On Equity | -2.0 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 231.8 M | ||||
| Shares Outstanding | 64.26 M | ||||
| Price To Earning | (5.64) X | ||||
| Price To Book | 22.01 X | ||||
| EBITDA | (26.88 M) | ||||
| Net Income | (27.03 M) | ||||
| Cash And Equivalents | 56.72 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.37 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.80 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (23.93 M) | ||||
| Earnings Per Share | (0.99) X | ||||
| Market Capitalization | 273.09 M | ||||
| Total Asset | 45.55 M | ||||
| Retained Earnings | (334.72 M) | ||||
| Working Capital | 21.09 M | ||||
| Current Asset | 78.53 M | ||||
| Current Liabilities | 6.42 M | ||||
About Corvus Pharmaceuticals Performance
Assessing Corvus Pharmaceuticals' fundamental ratios provides investors with valuable insights into Corvus Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Corvus Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (840.64) | (798.61) | |
| Return On Tangible Assets | (0.68) | (0.72) | |
| Return On Capital Employed | (0.70) | (0.73) | |
| Return On Assets | (0.68) | (0.72) | |
| Return On Equity | (0.80) | (0.76) |
Things to note about Corvus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Corvus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Corvus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Corvus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Corvus Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (27.03 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Corvus Pharmaceuticals currently holds about 56.72 M in cash with (23.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Corvus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 11b Clinical ... |
- Analyzing Corvus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Corvus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Corvus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Corvus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Corvus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Corvus Pharmaceuticals' stock. These opinions can provide insight into Corvus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.